China-approved Bevacizumab

BIOLOGICAL3 trials

Sponsors

Zhejiang Teruisi Pharmaceutical Inc.

Conditions

Advanced Non-squamous Non-small-cell Lung CancerHealthyMetastatic Colorectal Cancer (CRC)

Phase 1

A Study to Compare Pharmacokinetic and Safety of TRS003 to China-approved Bevacizumab and US-licensed Avastin®

CompletedNCT03882424

Zhejiang Teruisi Pharmaceutical Inc.Healthy

Start: 2018-06-12End: 2018-10-25Updated: 2020-06-16

Phase 3

A Study to Compare the Similarity in Efficacy and Safety Between TRS003 and China-approved Bevacizumab® in NSCLC

Zhejiang Teruisi Pharmaceutical Inc.Advanced Non-squamous Non-small-cell Lung Cancer

Start: 2020-08-17End: 2021-11-10Target: 608Updated: 2020-08-31

A Study Assessing the Interchangeability Between TRS003 and Bevacizumab® For CRC

Zhejiang Teruisi Pharmaceutical Inc.Metastatic Colorectal Cancer (CRC)

Start: 2022-08-01End: 2024-07-01Target: 126Updated: 2022-05-18